All patients with these sarcomas were treated with tumor AZD1390 mw resection and/or chemotherapy between 1988 and 2005. We performed brachytherapy or external radiation therapy following conservative surgery for all soft tissue sarcoma patients who received marginal resection. Chemotherapy comprised of multiagent systemic chemotherapy in metastatic patients. High dose ifosfamide, doxorubicin and/or cisplatin were used. We collected all primary tumor samples by tumor resection or biopsy, and no patients had undergone chemotherapy

before surgical specimens were collected. The study was approved by our institutional review board (Dai eki 133, and 263). Table 1 Data in 36 patients with soft tissue BLZ945 in vitro MFH Age (Yrs) Gender Site Histol. Type Prognosis Period (mos.) hTERT p38 53 Male thigh signaling pathway stori-pleo DOD 12 28.4 0 48 Male thigh myxoid NED 80 1564.5 0 76 Female thigh stori-pleo DOD 22 2365 8.7 54 Male thigh stori-pleo

DOD 12 978.4 6.1 49 Male upper arm stori-pleo DOD 18 22 2.8 63 Female axillary myxoid CDF 28 383.4 4.5 82 Male thigh stori-pleo CDF 80 181.9 3.3 66 Female thigh stori-pleo CDF 60 133.2 0 75 Male thigh stori-pleo NED 35 1986.5 2.8 45 Female inguinal myxoid CDF 27 8.5 0.3 78 Female thigh stori-pleo DOD 9 8.9 5.2 35 Male thigh stori-pleo CDF 52 1.9 2.1 81 Male thigh stori-pleo CDF 26 0 0 84 Male buttock stori-pleo CDF 26 45.9 10 57 Female shoulder stori-pleo CDF 62 158.3 36.2 76 Female thigh stori-pleo DOD 6 196.8 50.1 75 Male thigh stori-pleo DOD 10 147.3 15.6 57 Male thigh stori-pleo CDF 94 696.5 14.1 69 Male thigh stori-pleo CDF 94 18 60.3 72 Male thigh stori-pleo DOD 49 0 0.3 64 Female buttock myxoid DOD 10 2.6 10.3 55 Female thigh myxoid DOD 21 1029.5 aminophylline 23 59 Female shoulder stori-pleo DOD 47 2656 71.1 74

Male thigh myxoid DOD 27 15.6 0.4 59 Female lower leg inflammatory CDF 115 4.6 1.7 46 Male thigh stori-pleo CDF 98 0 0 73 Male thigh stori-pleo CDF 112 0 0 62 Female forearm myxoid CDF 138 145.3 5 59 Female thigh stori-pleo DOD 7 45.3 1.3 49 Male upper arm stori-pleo CDF 87 10.1 0 85 Male thigh stori-pleo CDF 106 0.9 0.2 58 Female buttock stori-pleo DOD 6 103.8 0.1 73 Male thigh stori-pleo CDF 112 145.3 0 78 Male lower leg stori-pleo CDF 119 125.1 0.2 71 Female lower leg myxoid NED 65 31.9 2.4 73 Female lower leg myxoid CDF 25 135.6 7.8 stori-pleo = storiform-pleomorphic type CDF = continuously disease-free NED = no evidence of disease DOD = died of disease Table 2 Data in 24 patients with liposarcoma Age (Yrs) Gender Site Histol. Type Prognosis Period (mos.) hTERT p38 65 Male thigh myxoid NED 93 4 0.4 35 Female popliteal myxoid CDF 108 31.6 1 50 Female thigh myxoid CDF 102 0 0.4 42 Male shoulder myxoid CDF 41 726.6 30.1 65 Male thigh myxoid CDF 56 484.9 38.2 66 Female thigh dediff.